Menarini Silicon Biosystems announces publication of the DETECT III trial results highlighting the potential clinical utility of HER2 testing in circulating tumor cells with CELLSEARCH

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Menarini-Trial-Result

More Like This

PR Newswire associated0

Menarini Silicon Biosystems announces new study results on use of CELLSEARCH® liquid biopsy for earlier detection of relapse and to help inform decisions on patient management in stage III Melanoma

PR Newswire associated0

CELLSEARCH® CTC count proves its clinical utility in guiding therapeutic strategy supporting patient care in HR+/HER2- metastatic breast cancer

PR Newswire associated0

/C O R R E C T I O N -- Menarini Silicon Biosystems/

PR Newswire associated0

Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU

First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer

PR Newswire associated0

European Organisation for Research and Treatment of Cancer & the Menarini Group Launch New Clinical Trial in Early-Stage Breast Cancer

Tracer Biotechnologies Announces Agreement for Next-Generation Cancer Monitoring for Drug Development

New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine